UriVarx | Clinically Proven Bladder Control | Promote and support healthy bladder function, help reduce frequency and maintain control

Clinically shown to support healthy bladder function,enhance bladder control and maintain decreased urinary frequency. PatentedUriVarx specifically targets the bladder and surrounding tissues to promotenormal urination and strong bladder tone. Unlike most dietary supplements,UriVArx has proven results from rigorous clinical trials to support the safetyand use of UriVArx in men and women. UriVArx supported the maintenance ofurinary frequency and improved the participants reported quality of life.UriVarx is a proprietary blend of the following botanical ingredients: Linderaextract (Lindera aggregate) is a root that has been used to support healthyurinary and kidney function.Horsetail extract (Equisetum arvense) is a plantlisted on the German Commission E monograph to support and maintain the healthof the urinary tract.Cratevox Three -leaf caper extract (Crateva nurvala) barkdemonstrated in pre-clinical studies to enhance bladder tone. In anuncontrolled clinical study, Crateva nurvala bark supported healthy urinaryfunction and bladder tone after 3 months of use. The ingredients formulatedand transferred into the system through a vegetable capsule (HPMC, water),along with inactive ingredients rice flour and silica. Read more UriVarx wasevaluated in an 8-week, double-blind, randomized, placebo-controlled, clinicalstudy conducted at two sites. UriVarx is clinically proven in an 8-week doubleblind placebo controlled clinical trial in 150 patients to support bladdertone and function. The results from a recent study found a: Reduction of ~56%in Urge IncontinenceReduction of ~66% in Stress IncontinenceReduction of ~61%in Urinary UrgencyReduction of ~33% in Urinary Frequency Reduction of ~46% inNocturia The total average reduction % of Urinary Frequency is found to be inthe normal/ideal range after two months of use. Read more Reduction of ~46% inNocturia UriVarx was more effective in reducing the frequency of day urinationand superior in reducing nocturnia. Reduction of ~61% in Urinary UrgencyUriVarx was assessed in 142 subjects (81 female and 61 male) on urinaryfrequency and urgency. Data was collected at 2, 4, and 8 weeks. Reduction of~66% in Stress Incontinence The primary outcome measure was self-reportedurinary frequency defined as the number of voluntary diurnal and/ or nocturnalmicturitions. Reduction of ~56% in Urge Incontinence There were no adverseevents leading to discontinuation. Read more